Christina Coughlin, formerly of Novartis, has joined Immunocore Ltd as chief medical officer. At Novartis, Dr Coughlin led two early development programmes in checkpoint inhibition and in P13 kinase inhibition. Prior to this she was international project team leader at Morphotek Inc, an antibody company that was acquired by Eisai Co Ltd in 2007.
Dr Coughlin has an MD and PhD from the University of Pennsylvania where she studied patient responses to tumour antigens with Robert Vonderheide in the division of translational research under the direction of Carl June.
Immunocore announced the appointment on 1 April 2015.
Copyright 2015 Evernow Publishing Ltd